Day-45 MRD clearance favored cema-cel over observation by an absolute 41.6% in the first 24 evaluable patients, satisfying ...
Allogene Therapeutics (NASDAQ:ALLO) detailed interim results from its pivotal Phase II ALPHA3 study during a business update ...
Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. New research offers insights into the use of axicabtagene ciloleucel (axi-cel), ...
Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results